Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials-Reference-Cited by-同舟云学术

Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials

Published:2021-05-21 Issue:9 Volume:62 Page:2169-2176
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Palomba M. Lia¹^ORCID,Jun Monika Parisi²,Lymp James³,Nguyen Andy⁴,McGarvey November⁴,Gitlin Matthew⁴,Pelletier Corey²,Keating Scott J.²,Godwin John⁵

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Bristol Myers Squibb, Princeton, NJ, USA

3. Bristol Myers Squibb, Seattle, WA, USA

4. BluePath Solutions, Los Angeles, CA, USA

5. Providence Cancer Center, Portland, OR, USA

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1910686

Reference32 articles.

1. US Cancer Statistics Working Group. US Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016) [Internet]. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention

2. 2019. [cited 2020 Oct 6]. Available from: https://gis.cdc.gov/Cancer/USCS/DataViz.html

3. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

4. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

5. Diffuse large B-cell lymphoma—treatment approaches in the molecular era

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mobilizing CARs: Benefits, Drawbacks, and Directions for Outpatient CAR T-cell therapy;Seminars in Hematology;2024-08

2. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma;Frontiers in Immunology;2024-06-10

3. Mechanisms and management of CAR T toxicity;Frontiers in Oncology;2024-05-21

4. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma;Future Oncology;2023-07

5. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications;Current Oncology;2023-05-15